Director Genitourinary and Phase 1 Programs
West Cancer Center and Research Institute
University of Tennessee Health Sciences Center
Germantown, Tennessee
Dr. Vaena completed his Hematology Oncology fellowship at Indiana University in 2004 and then joined the faculty at the University of Iowa Comprehesive Cancer Center, where he served as Director of the Clinical Trials Office among many other roles. He later transitioned to the West Cancer Center and Research Insitutite (Memphis, TN) in 2016, where he serves as Director of the Genitourinary and Experimental Therapeutics Programs with an active clinical practice in close collaboration with urologists for the management of bladder cancer accross the entire therapeutic space spectrum. Dr. Vaena has particular expertise in Genitourinary Oncology and early drug development with several publications, and has participated in innumerable urothelial carcinoma clinical trials including the early development of immunotherapy and novel targeted therapy. Dr. Vaena additionally serves as an auditor for the Alliance NCI Cooperative Group and is a genitourinary committee member in other clinical research consortia as well as participating in data safety monitoring activities at different institutions.
Aveo (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Bayer Healthcare Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Bristol-Meyers-Squibb (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Eisai (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; EMD SERONO (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Exelixis (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Genomic Health (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Immunomedics (Individual(s) Involved: Self): Advisory Board; Janssen (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Natera (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Seattle Genetics, (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board
Thursday, July 21, 2022
10:05 AM – 11:05 AM
Wednesday, September 7, 2022
2:20 PM – 3:20 PM